Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. (CELU), a Delaware corporation, filed this Current Report on Form 8-K on June 23, 2025. The filing discloses the entry into a Material Definitive Agreement and the unregistered sale of equity securities via a private placement.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Class A Common Stock.
- Shares Issued: 739,286 shares.
- Purchase Price: $1.40 per share.
- Gross Proceeds: Expected to be $1,035,000 before offering expenses.
- Use of Proceeds: Working capital and general corporate purposes.
- Warrant Adjustment: Exercise price for 1,311,093 existing warrants reduced to $2.50 per share; expiration extended to June 30, 2030.
- Closing Date: Expected during the week of July 21, 2025.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the capital raise through the private placement and the concurrent modification of warrant terms for participating investors. The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Contingencies
The closing of the transaction is subject to the satisfaction of customary closing conditions. The Company intends to utilize the net proceeds to support working capital needs. No specific forward-looking guidance or risk factors beyond standard closing contingencies are detailed in this specific filing text.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $1,035,000 gross proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination rights.
- Confirm the exact number of warrants adjusted and the impact on total outstanding warrant count.
- Monitor subsequent filings for the actual use of proceeds and any dilution effects on existing shareholders.